Regeneron Pharmaceuticals recently received U.S. FDA approval and a positive opinion from the European Medicines Agency's ...
GlobalData on MSN
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery
The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody ...
The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and ...
FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, ...
Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...
Regeneron Pharmaceuticals (REGN) has grabbed investor attention this week, as recent positive late-stage clinical data and a ...
The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ immunotherapy, Libtayo, as an add-on ...
The Commissioner’s National Priority Voucher awards companies that align with specific national priorities—such as boosting ...
GlobalData on MSN
FDA approves Celltrion’s Eydenzelt for eye diseases
Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron ...
Regeneron Pharmaceuticals' Libtayo won approval to treat certain patients with cutaneous squamous cell carcinoma, a type of skin cancer, from the Food and Drug Administration. The pharmaceutical ...
A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback